These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Use of mannitol to prevent amphotericin B nephrotoxicity. Fuller MA Clin Pharm; 1987 May; 6(5):367-8. PubMed ID: 3117480 [No Abstract] [Full Text] [Related]
27. Prevention of amphotericin B nephrotoxicity: the effect of salt loading and flucytosine. Heidemann H Mykosen Suppl; 1988; 2():39-44. PubMed ID: 3078022 [No Abstract] [Full Text] [Related]
28. [Advances in research on reducing toxicity of amphotericin B]. Xu XQ Zhonghua Nei Ke Za Zhi; 1989 Apr; 28(4):243-5. PubMed ID: 2680337 [No Abstract] [Full Text] [Related]
29. Mortality rates in comparative trials of formulations of amphotericin B. Frothingham R Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201 [No Abstract] [Full Text] [Related]
30. Drugs for the treatment of systemic fungal infections. Med Lett Drugs Ther; 1978 Jul; 20(15):66-8. PubMed ID: 661747 [No Abstract] [Full Text] [Related]
31. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. Aguado JM; Lumbreras C; González-Vidal D; Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408 [TBL] [Abstract][Full Text] [Related]
32. Current and future chemotherapy of central nervous system fungal infections. Utz JP Adv Neurol; 1974; 6():127-32. PubMed ID: 4480013 [No Abstract] [Full Text] [Related]
33. Poor immediate tolerability of amphotericin B lipid emulsion in patients with haematological malignancies. Haematology-Microbiology Group. Laverdière M; Habel F; Weiss K; Delorme J; Dubois G; Gagnon N; Bélanger R J Antimicrob Chemother; 1997 Dec; 40(6):910-2. PubMed ID: 9462450 [No Abstract] [Full Text] [Related]
37. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300 [TBL] [Abstract][Full Text] [Related]
38. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820 [TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacology of amphotericin B. Pyle RL J Am Vet Med Assoc; 1981 Jul; 179(1):83-4. PubMed ID: 7251466 [No Abstract] [Full Text] [Related]
40. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. Manzoni P; Galletto P; Rizzollo S; Franco C; Gallo E; Antonucci R; Fanos V; Farina D Early Hum Dev; 2012 May; 88 Suppl 2():S86-91. PubMed ID: 22633524 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]